230 related articles for article (PubMed ID: 25857446)
1. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Yokoyama H; Yano R; Kuroiwa H; Tsukada T; Uchida H; Kato H; Kasahara J; Araki T
Metab Brain Dis; 2010 Jun; 25(2):135-43. PubMed ID: 20424905
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Yokoyama H; Yano R; Kuroiwa H; Tsukada T; Uchida H; Kato H; Kasahara J; Araki T
Metab Brain Dis; 2010 Sep; 25(3):305-13. PubMed ID: 20957419
[TBL] [Abstract][Full Text] [Related]
4. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
5. Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson's Disease.
Biju KC; Evans RC; Shrestha K; Carlisle DCB; Gelfond J; Clark RA
Neuroscience; 2018 Jun; 380():111-122. PubMed ID: 29684508
[TBL] [Abstract][Full Text] [Related]
6. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
7. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
8. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
10. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
11. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
[TBL] [Abstract][Full Text] [Related]
12. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
Shin KS; Zhao TT; Choi HS; Hwang BY; Lee CK; Lee MK
Brain Res; 2014 Jun; 1567():57-65. PubMed ID: 24747613
[TBL] [Abstract][Full Text] [Related]
13. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
14. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Szego ÉM; Gerhardt E; Kermer P; Schulz JB
Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
[TBL] [Abstract][Full Text] [Related]
15. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Zhao Q; Cai D; Bai Y
Int J Mol Med; 2013 Oct; 32(4):883-91. PubMed ID: 23877198
[TBL] [Abstract][Full Text] [Related]
16. The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Na
Hossain MM; Weig B; Reuhl K; Gearing M; Wu LJ; Richardson JR
Exp Neurol; 2018 Oct; 308():111-119. PubMed ID: 30017881
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.
Jarras H; Bourque M; Poirier AA; Morissette M; Coulombe K; Di Paolo T; Soulet D
J Neuroendocrinol; 2020 Jan; 32(1):e12782. PubMed ID: 31430407
[TBL] [Abstract][Full Text] [Related]
18. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors.
Choudhury ME; Sugimoto K; Kubo M; Iwaki H; Tsujii T; Kyaw WT; Nishikawa N; Nagai M; Tanaka J; Nomoto M
Eur J Pharmacol; 2012 Aug; 689(1-3):72-80. PubMed ID: 22659113
[TBL] [Abstract][Full Text] [Related]
19. 17β-Estradiol/N-acetylcysteine interaction enhances the neuroprotective effect on dopaminergic neurons in the weaver model of dopamine deficiency.
Botsakis K; Theodoritsi S; Grintzalis K; Angelatou F; Antonopoulos I; Georgiou CD; Margarity M; Matsokis NA; Panagopoulos NT
Neuroscience; 2016 Apr; 320():221-9. PubMed ID: 26852701
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
